Drug Class: DPP-4 Inhibitor + Biguanide Antidiabetic Combination | Form: Extended-Release Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Tagipmet XR 50/500mg Tablet? Tagipmet XR 50/500mg contains Sitagliptin 50mg and Metformin Hydrochloride 500mg in an extended-release formulation — combining two complementary antidiabetic medicines with completely different and additive mechanisms of action in a single convenient tablet. The XR formulation releases Metformin gradually throughout the day — significantly reducing the gastrointestinal side effects such as nausea and diarrhoea that commonly occur with immediate-release Metformin, improving long-term tolerability and treatment compliance. Sitagliptin enhances natural insulin secretion while Metformin reduces liver glucose production and improves insulin sensitivity — together providing more comprehensive blood sugar control than either medicine alone while maintaining the low hypoglycaemia risk profile that makes this combination particularly suitable for long-term Type 2 diabetes management.
What is Tagipmet XR 50/500mg Used For?
- Type 2 diabetes — dual combination therapy when single antidiabetic medicine is insufficient (ذیابیطس ٹائپ 2 میں بلڈ شوگر کنٹرول)
- Step-up from Metformin monotherapy — adding Sitagliptin when Metformin alone provides inadequate HbA1c control
- Step-up from Sitagliptin monotherapy — adding Metformin when Sitagliptin alone is insufficient
- Simplifying regimen — replacing separate Sitagliptin and Metformin tablets with single combination tablet
- Type 2 diabetes with insulin resistance — Metformin's insulin-sensitising effect particularly beneficial
- Overweight Type 2 diabetic patients — Metformin's weight-neutral or modest weight-reducing effect advantageous
How Does it Work? Sitagliptin selectively inhibits DPP-4 enzyme — preventing breakdown of GLP-1 and GIP incretin hormones, increasing active incretin levels to stimulate glucose-dependent insulin secretion and suppress glucagon from pancreatic cells. This glucose-dependent mechanism means Sitagliptin only enhances insulin release when blood sugar is actually elevated — maintaining the low hypoglycaemia safety profile. Metformin primarily reduces hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis in the liver — the main source of fasting hyperglycaemia in Type 2 diabetes. Metformin also improves peripheral insulin sensitivity in muscle and fat tissue and reduces intestinal glucose absorption. The XR formulation releases Metformin slowly in the upper gastrointestinal tract — achieving equivalent glycaemic efficacy to immediate-release Metformin with significantly better gastrointestinal tolerability.
Dosage and Administration
⚠️ Swallow whole — never crush or chew the extended-release tablet. Take with evening meal for best Metformin tolerability and absorption. Temporarily stop before any surgical procedure or iodinated contrast imaging — Metformin and contrast media combination risks lactic acidosis. Monitor kidney function regularly — Metformin contraindicated in significant kidney impairment.
| Indication | Usual Adult Dose | Frequency | Notes |
|---|---|---|---|
| Type 2 diabetes — initial combination | 50mg/500mg | Once or twice daily with meals | Start once daily — increase if needed |
| Step-up from Metformin monotherapy | 50mg/500mg | Twice daily with meals | Replaces separate tablets |
| Step-up from Sitagliptin monotherapy | 50mg/500mg | Once or twice daily | As directed by diabetologist |
| Established combination therapy | 50mg/1000mg | Twice daily with meals | Higher Metformin strength if needed |
Active Ingredients
| Ingredient | Strength |
|---|---|
| Sitagliptin Phosphate Monohydrate | 50mg (as Sitagliptin) |
| Metformin Hydrochloride | 500mg (Extended-Release) |
Who Should NOT Take Tagipmet XR 50/500mg?
- Allergy to Sitagliptin, Metformin, or any component of the tablet
- Type 1 diabetes mellitus — not indicated
- Diabetic ketoacidosis — requires urgent insulin therapy
- Moderate to severe kidney impairment — GFR below 45ml/min; Metformin contraindicated due to lactic acidosis risk
- Severe liver impairment — Metformin contraindicated; lactic acidosis risk
- Acute or chronic conditions causing dehydration, tissue hypoxia, or shock — heart failure, respiratory failure, recent heart attack
- History of pancreatitis — Sitagliptin associated with pancreatitis risk
- Alcohol dependence — significantly increases lactic acidosis risk with Metformin
- Iodinated contrast imaging — temporarily stop Metformin before procedure
- Pregnancy and breastfeeding — insulin preferred during pregnancy
- Children under 18 years
Side Effects
Common: Mild nausea, mild stomach discomfort, mild diarrhoea — significantly reduced by XR formulation compared to immediate-release Metformin; taking with evening meal further reduces these effects. Mild headache, mild upper respiratory symptoms.
Serious — Stop and seek emergency help immediately: Lactic acidosis — rare but life-threatening Metformin complication; symptoms include severe muscle pain, difficulty breathing, stomach pain, dizziness, and feeling very cold (فوری ہسپتال جائیں — یہ طبی ہنگامی صورتحال ہے), acute pancreatitis — severe persistent upper abdominal pain radiating to back (پیٹ میں شدید درد — فوری مدد لیں), severe allergic reaction — swelling of face or throat with difficulty breathing (فوری ہسپتال جائیں), severe skin reactions — Stevens-Johnson syndrome with widespread blistering (فوری مدد لیں), significant disabling joint pain (جوڑوں کا شدید درد — ڈاکٹر کو بتائیں), worsening heart failure with breathlessness and ankle swelling (فوری مدد لیں), hypoglycaemia when combined with sulphonylurea or insulin (بلڈ شوگر کا گرنا — میٹھا کھائیں فوری).
Drug Interactions
| Medicine | Interaction |
|---|---|
| Iodinated contrast media | Metformin must be stopped before contrast procedure — combination risks serious lactic acidosis; restart only after kidney function confirmed normal 48 hours after procedure |
| Sulphonylureas (Glibenclamide, Glimepiride) | Significantly increased hypoglycaemia risk — sulphonylurea dose reduction typically required |
| Insulin | Increased hypoglycaemia risk — insulin dose adjustment under doctor supervision |
| Alcohol (شراب) | Significantly increases lactic acidosis risk from Metformin — avoid completely |
| Corticosteroids (Prednisolone) | Raise blood glucose — significantly impair effectiveness of both components; monitor closely |
| Diuretics (Furosemide, Thiazides) | Increase lactic acidosis risk through dehydration — monitor kidney function and hydration |
| ACE inhibitors / ARBs | May cause acute kidney impairment — monitor kidney function; reduced renal clearance increases Metformin accumulation risk |
| Beta-blockers | Mask hypoglycaemia warning signs — important when Tagipmet combined with sulphonylurea or insulin |
| Cimetidine | Significantly increases Metformin blood levels — increased lactic acidosis risk |
| Topiramate / Carbonic anhydrase inhibitors | Increased lactic acidosis risk with Metformin — avoid combination |
Storage: Store below 25°C in a cool, dry place. Protect from moisture and direct sunlight. Swallow whole — do not break or crush tablets. Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں). Do not use after expiry date.
FAQs
Q: Why must Tagipmet XR be stopped before a CT scan or angiography with contrast dye? Iodinated contrast media used in CT scans and angiography can temporarily impair kidney function — if Metformin is present during this kidney impairment it accumulates rapidly and causes potentially fatal lactic acidosis. Tagipmet XR must be stopped at least 48 hours before any planned contrast procedure and only restarted after kidney function is confirmed normal — always inform your radiologist and doctor about Metformin use before any imaging procedure.
Q: Why is the XR formulation better tolerated than regular Metformin tablets? The extended-release mechanism delivers Metformin slowly in the upper gastrointestinal tract over several hours — avoiding the high peak concentrations in the gut that cause the nausea, stomach cramps, and diarrhoea associated with immediate-release Metformin. Taking the XR tablet with the evening meal further smooths absorption and significantly improves long-term tolerability and treatment compliance.
Q: Can Tagipmet XR completely replace separate Sitagliptin and Metformin tablets? Yes — Tagipmet XR 50/500mg delivers exactly the same therapeutic effect as taking Sitagliptin 50mg and Metformin XR 500mg as separate tablets. The fixed-dose combination simplifies the daily medicine routine to a single tablet — improving compliance which is critically important for long-term diabetes management and HbA1c target achievement.
Medical Disclaimer: This information is for general awareness only and does not replace medical advice. Always consult a qualified doctor or pharmacist before taking any prescription medicine.